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Bultot L, Jensen TE, Lai Y, Madsen AL, Collodet C, Kviklyte
S, Deak M, Yavari A, Foretz M, Ghaffari S, Bellahcene M,
Ashrafian H, Rider MH, Richter EA, Sakamoto K. Benzimidazole
derivative small-molecule 991 enhances AMPK activity and glucose
uptake induced by AICAR or contraction in skeletal muscle. Am J
Physiol Endocrinol Metab 311: E706–E719, 2016. First published
August 30, 2016; doi:10.1152/ajpendo.00237.2016.—AMP-activated
protein kinase (AMPK) plays diverse roles and coordinates complex
metabolic pathways for maintenance of energy homeostasis. This
could be explained by the fact that AMPK exists as multiple hetero-
trimer complexes comprising a catalytic -subunit (1 and 2) and
regulatory  (1 and 2)- and  (1, 2, 3)-subunits, which are
uniquely distributed across different cell types. There has been keen
interest in developing specific and isoform-selective AMPK-activat-
ing drugs for therapeutic use and also as research tools. Moreover,
establishing ways of enhancing cellular AMPK activity would be
beneficial for both purposes. Here, we investigated if a recently
described potent AMPK activator called 991, in combination with the
commonly used activator 5-aminoimidazole-4-carboxamide riboside
or contraction, further enhances AMPK activity and glucose transport
in mouse skeletal muscle ex vivo. Given that the 3-subunit is
exclusively expressed in skeletal muscle and has been implicated in
contraction-induced glucose transport, we measured the activity of
AMPK3 as well as ubiquitously expressed 1-containing complexes.
We initially validated the specificity of the antibodies for the assess-
ment of isoform-specific AMPK activity using AMPK-deficient
mouse models. We observed that a low dose of 991 (5 M) stimulated
a modest or negligible activity of both 1- and 3-containing AMPK
complexes. Strikingly, dual treatment with 991 and 5-aminoimida-
zole-4-carboxamide riboside or 991 and contraction profoundly en-
hanced AMPK1/3 complex activation and glucose transport com-
pared with any of the single treatments. The study demonstrates the
utility of a dual activator approach to achieve a greater activation of
AMPK and downstream physiological responses in various cell types,
including skeletal muscle.
AMP-activated protein kinase; LKB1; compound 13; A769662; 991;
ex229; 5-aminoimidazole-4-carboxamide riboside
AMP-ACTIVATED PROTEIN KINASE (AMPK) is an important energy
sensor that maintains energy homeostasis by coordinating
metabolic pathways/processes in response to energy supply
and demand (38). During metabolic stress, the cellular AMP-
to-ATP ratio increases, leading to the activation of AMPK,
which, in turn, switches off energy-consuming anabolic path-
ways and switches on catabolic pathways to restore ATP
levels. One of the most physiological metabolic stresses that
activates AMPK is skeletal muscle contraction, which contrib-
utes at least partly to an increase in glucose uptake by promot-
ing glucose transporter (GLUT)4 translocation to the plasma
membrane by phosphorylating candidate mediators such as
TBC1 domain family member 1 and FYVE domain-containing
phosphatidylinositol 3-phosphate 5-kinase (15, 21, 25, 30, 32).
AMPK is a heterotrimer comprising a catalytic -subunit
and regulatory - and -subunits. Multiple isoforms encoded
by distinct genes exist (1 and 2, 1 and 2, and 1, 2, and
3), which can theoretically form several distinct heterotri-
meric combinations (14, 38). Isoform expression varies among
cells/tissues and also species (40, 45), with 1, 1, and 1
appearing in general to be ubiquitously expressed isoforms.
Some isoforms are expressed in a cell/tissue-specific/restricted
manner. For example, 2 is more predominantly expressed in
skeletal muscle (26) and 3 is exclusively detected in skeletal
muscle, especially in glycolytic muscle fibers (5, 49). The
-subunits contain four tandem cystathionine -synthase
(CBS) repeats that bind adenine nucleotides. AMPK activity
increases upon phosphorylation of a conserved threonine
residue in the T-loop (T172) (14). Binding of ADP and/or
AMP to CBS repeats induces conformational changes that
promote net T172 phosphorylation by the enhancement of
T172 phosphorylation and suppression of T172 dephosphor-
ylation (13, 27, 47). Moreover, the binding of AMP (but not
ADP) further increases AMPK activity by direct allosteric
stimulation (13). The major upstream kinase phosphorylat-
ing T172 in metabolic tissues (e.g., muscle and liver) is a
complex containing LKB1 (33, 37), which appears to be
constitutively active (1, 31).
AMPK activation has favorable effects on carbohydrate and
lipid metabolism in the skeletal muscle and liver, and there has
been keen interest in developing AMPK-activating drugs for
therapeutic use in the treatment of metabolic diseases, such as
type 2 diabetes. Cool et al. (6) described the identification of
the thienopyridone A769662, the first small-molecule direct
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activator of AMPK. A769662, like AMP, inhibits T172 de-
phosphorylation (12, 34), although it does not bind to adenine
nucleotide-binding sites on the -subunit. The oral absorption
of this compound is poor. However, when injected intraperi-
toneally, it displayed antidiabetic effects, including reduced
weight gain, decreased plasma glucose and triglycerides, and
decreased liver triglycerides in obese mice (6). In addition,
A769662 is a valuable research tool, although its utility is
limited by the marked selectivity toward complexes containing
1 rather than 2 isoforms (36). Consequently, it robustly
stimulates AMPK in mouse hepatocytes (where 1 is predom-
inantly expressed) and modulates lipid metabolism via an
AMPK-dependent mechanism (9, 18). In mouse skeletal mus-
cle, 2 is predominantly expressed, whereas only a modest
amount of 1 is detectable (39, 43). It has been shown that
incubation of isolated mouse skeletal muscle ex vivo with
A769662 failed to stimulate glucose uptake at 100–200 M.
At a much higher concentration (2 mM), A769662 stimulated
glucose uptake; however, it was mediated through an AMPK-
independent/phosphoinositide 3-kinase-dependent mechanism
due to unknown off-target effect(s) (43). Another small-mole-
cule AMPK activator, 991 [also known as ex229 (22)], has
recently been described. Structural studies have shown that 991
binds to a site formed between the small lobe of the -subunit
kinase domain and the -subunit carbohydrate-binding module
(4, 46), which is also the binding site for A769662, termed the
allosteric drug and metabolite-binding site (ADaM) (23). 991
is 5- to 10-fold more potent than A769662 in cell-free assays
(46) and has been shown to stimulate AMPK activity of both
1- and 2-containing complexes and to increase glucose
transport in isolated mouse skeletal muscle ex vivo (22).
Establishing a means to augment cellular AMPK activation
would potentially enhance the therapeutic effects of future
AMPK activators and in fundamental research allow more
robust biochemical and functional analyses in intact cells/
tissues. We (8, 11, 41) and others (35) have shown that dual
AMPK-activating compound treatment [A769662 and 5-ami-
noimidazole-4-carboxamide riboside (AICAR)] resulted in ad-
ditive/synergistic increases in cellular AMPK activity and
downstream physiological effects, such as inhibition of lipo-
genesis in hepatocytes (8). One limitation of the A769662 and
AICAR dual treatment is that the additive or synergistic effects
can only be produced in cells where 1 is predominantly
expressed (e.g., mouse hepatocytes), as the effects were absent
in 1-deficient cells (8). In the present study, we explored
whether treatment with the potent ADaM site-binding agent
991 would enhance the effect of the canonical adenine nucle-
otide binding-mediated activation of AMPK by AICAR and
contraction in mouse skeletal muscle. Given that activation of
3-containing complexes (especially 223) is associated
with AICAR- and contraction-mediated glucose uptake (2, 3),
we assessed the effect of 991 alone and in combination with
AICAR or contraction on activating AMPK1 and AMPK3
complexes. We demonstrated that a low dose of 991 results in
only a modest or negligible activation of 1- and 3-containing
AMPK complexes in mouse skeletal muscle. However, strik-
ingly, dual treatment with 991 and AICAR or 991 and con-
traction profoundly enhanced AMPK activation and glucose
transport compared with single agonist treatments.
MATERIALS AND METHODS
Materials. AICAR was from Toronto Research Chemicals.
A769662 was from Selleck Chemicals. Compound 13 was obtained as
previously described (18). 991 (5-{[6-chloro-5-(1-methylindol-5-yl)-
1H-benzimidazol-2-yl]oxy}-2-methyl-benzoic acid; CAS no. 129739-
36-2) as obtained as previously described (7). Protein G Sepharose
was from GE Healthcare, and FLAG-M2 resin from Sigma-Aldrich.
ECL reagent and P81 filter papers were obtained from GE Healthcare.
[-32P]-ATP was from Perkin-Elmer. AMARA, LKBtide, and Saka-
mototide substrate peptides were synthesised by GL Biochem. The
COS1 cell line was obtained from American Type Culture Collection,
and the C2C12 cell line was obtained from Sigma-Aldrich. Frozen
tissues or extracts from AMPK1-/2-, AMPK1-/2-, and
AMPK3-deficient mice were obtained from Benoit Viollet and Marc
Foretz (Institut National de la Santé et de la Recherche Médicale,
Institut Cochin, Paris, France), Gregory Steinberg (McMaster Univer-
sity, Hamilton, ON, Canada), and Alexander Chibalin and Juleen
Zierath (Karolinska Institutet, Stockholm, Sweden), respectively. All
cell culture reagents were purchased from Thermo Fisher Scientific,
and all other chemicals were from Sigma-Aldrich unless otherwise
stated.
Antibodies. AMPK1/2 (no. 2532), phosphorylated (p)T172
AMPK (no. 2535), AMPK1 (no. 4182), AMPK2 (no. 4148),
AMPK1/2 (no. 4150), pS79 acetyl-CoA carboxylase (ACC; no.
3661), ACC (no. 3676), pS792 regulatory associated protein of
mechanistic target of rapamycin (RAPTOR; no. 2083), and RAPTOR
(no. 2280) were from Cell Signaling Technology. FLAG (F7425) and
-tubulin (T6074) antibodies were from Sigma-Aldrich. AMPK2
(sc-19141) and creatine kinase (sc-15161) antibodies were from Santa
Cruz Biotechnology. AMPK1 (no. 07-350) and AMPK2 (no.
07-363) antibodies were obtained from Millipore. For immunopre-
cipitation, the antibody for AMPK1 (A4856) was from Sigma-
Aldrich and the antibody for AMPK2 (MAB3808) was from R&D
Systems. AMPK1 and AMPK2 antibodies used for immunopre-
cipitation were as previously described (33). LKB1 and salt-inducible
kinase (SIK)3 antibodies have also been previously described (31).
The following polyclonal antibodies were generated by YenZym
Antibodies by immunizing rabbits with the indicated peptides: a
combination of human AMPK3 peptide [residues S45–S65: *CS-
SERIRGKRRAKALRWTRQKS; a terminal cysteine (*C) was added
to the peptide sequence to allow peptide conjugation to carrier
proteins], mouse AMPK3 peptide (residues S44–S64: *CSSERT-
CAIRGVKASRWTRQEA), and AMPK1 peptide (residues E7–S26
of mouse AMPK1: *CESSPALENEHFQETPESNNS). The pro-
duced antibodies were affinity purified using respective antigen-
specific peptide columns by YenZym Antibodies. Horseradish perox-
idase-conjugated secondary antibodies were from Jackson Immu-
noResearch.
Kinase inhibition screening. Kinase inhibition screening was
performed by the International Centre for Kinase Profiling (Uni-
versity of Dundee) using [-33P]phosphotransferase assays (MRC
Protein Phosphorylation and Ubiquitylation Unit, http://www.kinase-
screen.mrc.ac.uk/).
Molecular cloning. The coding region of human AMPK1 (NM_
002733), AMPK2 (NM_016203.3), and AMPK3 (NM_017431) was
amplified from muscle RNA (Agilent) using a Superscript III 1 step
RT PCR kit (Invitrogen). The resulting PCR products were either
ligated into intermediate vector (pSC Agilent) or digested with the
relevant restriction enzymes and ligated directly into the mammalian
expression vector (pCMV5 acc. AF239249), which was modified to
incorporate a NH2-terminal FLAG tag. Sequences of all clones were
verified in house at the Nestlé Institute of Health Sciences using the
BigDye Terminator 3.1 kit and 3500XL Genetic analyzer (Applied
Biosystems).
Recombinant muscle-specific AMPK trimeric complex. Human
AMPK 223 was expressed in Esherichia coli using a tricistronic
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construct activated with Ca2/calmodulin-dependent protein kinase
kinase- in vitro and then purified and assayed as previously de-
scribed (18).
Animals. Animal experiments were approved by the local ethics
committee and conducted in accordance with the European Conven-
tion for the Protection of Vertebrate Animals used for Experimental
and Other Scientific Purposes. Protocols used were approved by
the Service Vétérinaire Cantonal (Lausanne, Switzerland) under
license VD2841 or approved by the University of Oxford Animal
Care and Ethical Review Committee and conformed with the
United Kingdom Animals Scientific Procedures Act 1986, incorpo-
rating European Directive 2010/63/EU (no. 30/2977), or approved
by the Danish Animal Experiments Inspectorate or approved by
the University of Paris-Descartes ethics committee (no.
CEEA34.BV.157.12) and performed under French authorization to
experiment on vertebrates (no. 75-886) in accordance with European
guidelines. The generation of AMPK1/ mice has been previously
described (10). Global AMPK2/ mice were generated by deleting
the entire exon 7 of the gene encoding AMPK2 in R299Q knockin
mice using Sox2cre-driven excision (48). Mice were maintained on a
standard chow diet and 12:12-h light-dark cycle.
Cell and tissue extract preparation. After treatment, cells were
washed once with PBS and scraped into ice-cold lysis buffer [con-
taining 50 mM Tris·HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 270
mM sucrose, 1% (wt/vol) Triton X-100, 20 mM glycerol-2-phosphate,
50 mM NaF, 5 mM Na4P2O7, 1 mM DTT, 0.1 mM PMSF, 1 mM
benzamidine Cl, 1 g/ml microcystin-LR, 2 g/ml leupeptin, and 2
g/ml pepstatin A]. Frozen tissues were homogenised using a poly-
tron PT 2500 E (Kinematica) in ice-cold lysis buffer. Cell/tissue
lysates were clarified by centrifugation at 3,500 g for 15 min at 4°C,
and protein concentration was measured using Bradford reagent and
BSA as a standard.
Cell culture. COS1, mouse embryonic fibroblast, and C2C12 cells
were maintained in DMEM GlutaMAX (Thermo Fisher Scientific)
supplemented with 10% (vol/vol) FBS and antibiotics. C2C12 myo-
blasts were differentiated into myotubes by 7 days of culture in
DMEM GlutaMAX supplemented with 2% (vol/vol) horse serum, 100
U/ml penicillin G, and 100 g/ml streptomycin. COS1 cells were
grown in 6-cm dishes and transfected at 60–70% confluency with 3.7
g plasmid prebound to 10.5 g polyethylenimine in 50 mM HEPES
(pH 7.4) and 150 mM NaCl. Cell culture medium was changed once
at 24 h after transfection, and cells were left for an additional 24 h
before compound treatment. Mouse embryonic fibroblast cells were
grown in 10-cm dishes and treated as indicated at 80–90% conflu-
ency. Primary mouse hepatocytes were isolated from C57BL/6NTac
male mice (Taconic) by collagenase perfusion, as previously de-
scribed (18, 29). Hepatocytes were seeded in medium 199 containing
100 U/ml penicillin G, 100 g/ml streptomycin, 0.1% (wt/vol) BSA,
10% (vol/vol) FBS, 10 nM insulin, 200 nM triiodothyronine, and 100
nM dexamethasone. Hepatocytes were left for attachment (3–4 h) and
cultured overnight in medium 199 supplemented with antibiotics and
100 nM dexamethasone. Cells were used for experiments the follow-
ing morning.
Immunoblot analysis. Cell or tissue lysates were denatured in
Laemmli buffer at 95°C for 5 min and separated by Tris-glycine
SDS-PAGE and transferred onto polyvinylidene difluoride mem-
branes. Membranes were blocked for 1 h at room temperature in 20
mM Tris·HCl (pH 7.6), 137 mM NaCl, and 0.1% (vol/vol) Tween 20
(Tris-buffered saline with Tween 20) containing 5% (wt/vol)
skimmed milk. Membranes were incubated in primary antibody pre-
pared in Tris-buffered saline with Tween 20 containing 5% (wt/vol)
BSA or skimmed milk overnight at 4°C. Signal detection was per-
formed using horseradish peroxidase-conjugated secondary antibodies
and ECL.
Immunoprecipitation and kinase activity assay. Cell or tissue ly-
sates were incubated with the indicated antibodies (shown in Fig. 2F)
precoupled to protein G-Sepharose for 1 h at 4°C. Immune complexes
were pelleted at 500 g for 1 min and washed twice with 0.5 ml lysis
buffer containing 500 mM NaCl and twice with 0.5 ml buffer A [50
mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EGTA, and 1 mM DTT]
and eluted with Laemmli buffer for analysis by immunoblotting or
assayed directly for kinase activity. The AMPK activity assay was
performed as previously described (19). Briefly, beads were incubated
45 min at 30°C under agitation in buffer A supplemented with 10 mM
magnesium acetate, 100 M ATP, and 200 M AMARA peptide
(NH2-AMARAASAAALARRR-COOH) in the presence of [-
32P]ATP (1 Ci). Reactions were terminated by spotting reaction
mixtures onto P81 filters and immersion in 75 mM phosphoric acid.
Washed filters were dried, and 32P incorporation into the substrate
AMARA peptide was measured by Cherenkov counting.
LKB1 and SIK3 assays were performed as previously described
(31), and activity was measured using LKBtide and Sakamototide (16)
as substrates, respectively.
Incubation, contraction, and glucose uptake in isolated mouse
skeletal muscle. Mice were euthanized by cervical dislocation, and
extensor digitorum longus (EDL) muscles were rapidly removed and
mounted on an incubation apparatus. The EDL muscle was incubated
as previously described (20) in the presence of 991 or vehicle (0.1%
DMSO) for 60 min with or without AICAR or in the presence of 991
or vehicle (0.1% DMSO) for 45 min with or without contraction
evoked via electrical stimulation (1 Hz, 0.1-ms square wave 30-V
pulses) (42) for 15 min. 2-Deoxy-[3H]glucose uptake was measured
during the last 10 min of the incubation or contraction period of each
experiment, as described previously (20).
Statistical analysis. Results are expressed as means  SE (unless
otherwise stated) for the indicated number of individual experiments.
Statistical significance was assessed using a paired two-sided Stu-
dent’s t-test (Fig. 3) or one-way ANOVA. When ANOVA revealed
significant differences, further analysis was performed using Fisher’s
least-significant-difference post hoc test for multiple comparisons
(Figs. 4–7). Differences between groups were considered statistically
significant at P 	 0.05.
RESULTS
Validation of AMPK-, -, and -isoform-specific antibod-
ies for immunoblot analysis. To investigate the effect of dual
treatments on AMPK isoform/complex-specific activity using
cell or tissue extracts in subsequent experiments, we initially
performed an extensive characterization/validation of the
AMPK isoform-specific antibodies. We verified the specificity
of AMPK1, AMPK2, AMPK1, and AMPK2 antibodies
for immunoblot analysis using the respective isoform-specific
AMPK knockout (KO) liver tissue extracts as controls (Fig. 1,
A and B). The specificity of the AMPK antibodies has not
been well documented, and we first assessed cross-reactivity of
the antibodies using recombinant proteins. Individual con-
structs encoding FLAG-tagged human AMPK1, AMPK2, or
AMPK3 were transfected in COS1 cells, and all three -iso-
forms were isolated from cell lysates using anti-FLAG anti-
body coupled to protein G-Sepharose. Immunoblot analysis of
the FLAG-immunoprecipitates confirmed that similar amounts
of each AMPK -isoform were isolated from the lysates (Fig.
1C, top left). We next immunoblotted the immunoprecipitates
with AMPK 1-, 2-, or 3-isoform-specific antibodies. As
shown in Fig. 1C (top right and bottom), each antibody only
detected the corresponding AMPK -isoform. We then tested
the specificity of the  antibodies against the endogenous
subunit protein using tissue extracts from wild-type (WT)
versus isoform-specific AMPK KO mice. As shown in Fig. 1,
D–F, each isoform-specific antibody detected a band at the
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Fig. 1. Validation of AMP-activated protein kinase (AMPK) isoform-specific antibodies for immunoblot (IB) analysis. A and B: IB analysis was performed with
20 g liver tissue protein extracts from wild-type (WT) and AMPK1/2 knockout (KO) mice (A) as well as AMPK1/2 KO mice (B) using the indicated
antibodies. IP, immunoprecipation. C: FLAG-tagged human AMPK1, AMPK2, and AMPK3 were ectopically expressed in COS1 cells, and cell extracts were
generated. All three AMPK isoforms were immunoprecipitated with anti-FLAG antibody and immunoblotted with the indicated antibodies. D–F: IB analysis
was performed with 20 g of the indicated tissue extract proteins from WT and isoform-specific AMPK KO mice using the indicated antibodies. Gas,
gastrocnemius; EDL, extensor digitorum longus; Sol, soleus. G: a panel of mouse tissue extracts (male C57BL/6NTac mice) was immunoblotted with the
indicated antibodies. Sk, skeletal PKB, protein kinase B. Representative blots are shown from n 
 1–3 mice/tissues.
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expected relative molecular mass in WT tissue extracts but not
in the corresponding KO tissue extracts. AMPK1 was ex-
pressed similarly in the three muscle types measured: gastroc-
nemius (glycolytic/oxidative fibers mixed), EDL (predomi-
nantly containing glycolytic fibers), and soleus (predominantly
containing oxidative fibers). AMPK3 was expressed in the
gastrocnemius and EDL but not in soleus (Fig. 1F), consistent
with previous reports (2, 49). Of note, AMPK2 was not
detectable in skeletal muscle, although it could be detected in
the liver and heart (Fig. 1E). Immunoblot analysis of a selec-
tion of mouse tissue extracts using the validated AMPK iso-
form-specific antibodies (Fig. 1, A–F) verified the exclusive
expression of AMPK3 in skeletal muscle and predominant
expression of AMPK1 in white adipose (Fig. 1G). Predomi-
nant expression of AMPK1 in the liver and AMPK2 in the
skeletal muscle, as well as the ubiquitous expression of
AMPK1, was also confirmed. It has been previously reported
that in mouse glycolytic skeletal muscle (EDL), 1 expression
represents only 5% of total -subunit expression (43), and
1 expression was not detectable with immunoblot analysis
(20 g lysates; Fig. 1G), even with longer film exposure (data
not shown). AMPK2 was broadly expressed, but its expres-
sion appeared relatively low (considering the levels of loading
control: -tubulin and protein kinase B) in the heart and was
not detectable in skeletal muscle (Fig. 1, E and G).
Validation of AMPK - and -isoform-specific antibodies
for immunoprecipitation. We next examined the specificity and
efficiency of the AMPK - and -isoform-specific antibodies
for immunoprecipitation using mouse tissue extracts [specific-
ity of AMPK1/2 antibodies for immunoprecipitation has
been previously described (33)]. We verified that each isoform-
specific antibody immunoprecipitated the corresponding
AMPK - and -subunit proteins (using extracts from WT
animals) in a specific and nearly complete manner (Fig. 2,
A–E). There was no immunoreactive band/signal detected in
extracts from the corresponding AMPK KO lysates and only a
negligible amount of proteins detected in the supernatant that
had been incubated with the corresponding antibody. More-
over, we confirmed that each AMPK - and -isoform-specific
antibody could precipitate its known interacting AMPK - and
-subunit isoform(s) [i.e., AMPK and AMPK proteins were
identified in  antibody immunoprecipitates (43); Fig. 2A]
from the tissue extracts (Fig. 2, A–E).
In summary, we validated AMPK isoform-specific antibod-
ies for both immunoblot analysis and immunoprecipitation.
Given that we used several antibodies for different applications
in the present study, a summary of the antibody list is shown in
Fig. 2F.
Effect of a small-molecule AMPK activator, 991, on a panel
of protein kinases in vitro. We screened compound 991, a
recently described potent AMPK activator (22, 46), at a con-
centration of 1 M in cell-free assays against a panel of 139
protein kinases, including AMPK (Fig. 3A). As anticipated,
recombinant AMPK complex [human 1(11–559)2(1–272)-
1(11–331)] was activated70% (highlighted in gray in Fig. 3A),
whereas none of the other kinases, including upstream kinases for
AMPK (LKB1 and Ca2/calmodulin-dependent protein kinase
kinase-, highlighted in gray) and members of AMPK-related
kinases (1) [BR serine/threonine kinase (BRSK)1, BRSK2,
SIK2, SIK3, microtubule affinity regulating kinase (MARK)2,
MARK3, MARK4, and maternal embryonic leucine zipper
kinase, highlighted in gray] were significantly affected (Fig.
3A). We have confirmed that 991 robustly stimulates recom-
binant muscle-specific AMPK223 complex in a separate
gold standard kinase activity assay in vitro [vehicle (DMSO):
496  123 (SD) vs. 991, 3,380  679 pmol Pi in-
corporated·min1·mg1, P 	 0.05]. Furthermore, in mouse
embryonic fibroblasts 991 increased the phosphorylation of
AMPK and its substrates ACC and RAPTOR (Fig. 3B).
Consistent with this observation (Fig. 3B) and in vitro screen
data (Fig. 3A), 991 robustly stimulated AMPK1 activity (Fig.
3C) but not LKB1 or SIK3 (Fig. 3, D and E). These results
suggest that 991 is a specific activator of AMPK at least in
vitro and to a limited extent in intact cells.
Enhanced activation of cellular AMPK activity by dual
compound treatment in hepatocytes. We tested if the effect of
991 [which binds to a site formed between the small lobe of the
-subunit kinase domain and the -subunit carbohydrate-bind-
ing module (46)] on AMPK activity could be further increased
when it was coincubated with another compound, AICAR or
C13 [which binds to the CBS domain of the -subunit, mim-
icking the action of AMP (18, 24)] in mouse primary hepato-
cytes. Hepatocytes were incubated with increasing concentra-
tions of 991 (ranging from 0 to 0.3 M) in the presence or
absence of AICAR (0.1 mM) or C13 (10 M) for 1 h, and
phosphorylation of AMPK and its bona fide substrates (i.e.,
ACC and RAPTOR) was assessed by immunoblot analysis as
surrogate markers of cellular AMPK activity (Fig. 4A). Treat-
ment of hepatocytes with 991 alone resulted in a slight increase
in the phosphorylation of AMPK and RAPTOR only at 0.3
M, whereas a robust increase in ACC phosphorylation was
readily observed and saturated at a concentration of 0.03 M 991.
AICAR or C13 alone robustly increased T172 phosphorylation of
AMPK, and when 991 was coincubated, there was a modest
additional dose-dependent increase in AMPK phosphorylation
(as judged by increased band density and slower-migrating spe-
cies). Single AICAR or C13 treatment caused ACC phosphory-
lation to saturating levels. In contrast, RAPTOR phosphoryla-
tion was modestly increased by AICAR or C13 alone, and it
was dose dependently increased when coincubations were
carried out with 991 (Fig. 4A). These data are consistent with
our previous observation that RAPTOR phosphorylation re-
quires a higher threshold of AMPK activity than ACC phos-
phorylation in mouse hepatocytes (18).
To assess the effects of single or dual agonist treatment on
the activities of specific AMPK isoforms/complexes in hepa-
tocytes, we next performed an in vitro quantitative AMPK
activity assay after immunoprecipitation with specific AMPK
subunit isoform antibodies (Fig. 4, B–G). As anticipated, the
activity of both AMPK1- and AMPK2-containing com-
plexes (Fig. 4, B and C) resembled the results of AMPK T172
phosphorylation (Fig. 4A) in response to compound treatments.
Of note and consistent with our previous observation (18),
incubation with C13 alone more robustly stimulated the activ-
ity of AMPK1-containing complexes, whereas AICAR treat-
ment increased the activation of AMPK1 and AMPK2 in a
relatively similar manner. However, the absolute activity
achieved by C13 was similar between 1 and 2, whereas
AICAR caused much higher absolute activation for 2 (Fig. 4,
B and C). In the mouse liver, AMPK1 is the predominant
isoform, whereas expression of AMPK2 is marginal (9).
Activity of AMPK1-containing complexes displayed a simi-
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lar activation profile (Fig. 4D) to the activity of AMPK1- and
AMPK2-containing complexes (Fig. 4, A and B). As ex-
pected, AMPK activity associated with AMPK2 complexes
was much lower than AMPK1 complexes and was robustly
activated by AICAR or C13. However, there was no further
activation when 991 was incubated along with AICAR or C13
(Fig. 4E). This might be due to the fact that 991 has a higher
affinity for AMPK1 (in cell-free assay) (46) and thus the low
concentrations of 991 used were not sufficient to stimulate the
activity of AMPK2-containing complexes. We then measured
AMPK activity associated with AMPK1 or AMPK2 and
observed that treatment with AICAR alone showed similar and
significant increases in AMPK activity of complexes associ-
ated with both isoforms, although the extent of activation was
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AMPK α1 07-350 Millipore Human AMPK α1 (376-392) 1A, 1G, 2B, 2D, 5A
AMPK α2 07-363 Millipore Human AMPK α2 (353-367) 1A, 1G, 2A, 2B, 2C, 2D, 2E, 5A, 5C
AMPK α1/α2 2532 Cell Signaling Technology Human AMPK α (N-term) 4A, 5B, 7A,
AMPK β1 4182 Cell Signaling Technology Human AMPK β1 (N-term) 1B, 1G, 2B, 2D, 5A
AMPK β2 4148 Cell Signaling Technology Human AMPK β2 2A, 2C, 5A, 5C
AMPK β1/β2 4150 Cell Signaling Technology Human AMPK β1 (Surrounding H233) 1B, 1G, 2E
AMPK γ1 Custom Mouse AMPK γ1 (7-26) 1C, 1D, 1G, 2A, 2D, 2C, 5A, 5C
AMPK γ2 sc-19141 Santa Cruz Human AMPK γ2 (N-term) 1C, 1E, 1G, 2B, 2 D
AMPK γ3 Custom Human AMPK γ3 (45-65) + Mouse AMPK γ3 (44-64) 1C, 1F, 1G, 2C, 5A, 5C
AMPK isoform Cat # Supplier Epitope Figures
AMPK α1 Custom Rat AMPK α1 (344-358) 4B
AMPK α2 Custom Rat AMPK α2 (352-366) 4C
AMPK β1 A4856 Sigma-Aldrich Human AMPK β1 (1-18) 2D, 4D
AMPK β2 MAB3808 R&D Systems Human AMPK β2 (1-272) 2E, 4E
AMPK γ1 Custom Mouse AMPK γ1 (7-26) 2A, 4F, 5C, 5D, 6C, 7C
AMPK γ2 sc-19141 Santa Cruz Human AMPK γ2 (N-term) 2B, 4G
AMPK γ3 Custom Human AMPK γ3 (45-65) + Mouse AMPK γ3 (44-64) 2C, 5C, 5E, 6D, 7D
Western blot
Summary of the AMPK antibodies used in the current study
Immunoprecipitation
Fig. 2. Validation of AMPK isoform-specific antibodies for IP. A–E: Endogenous AMPK complexes were immunoprecipitated using the indicated antibodies
from 200 g extract protein from the gastrocnemius muscle (A and C) or liver (B, D, and E) of the indicated AMPK WT or KO mice. IB analysis was performed
on the input (10% 
 20 g), the supernatant (SN; 10% 
 20 g), and the immunoprecipitates (IP) with the indicated antibodies. F: summary table of the
isoform-specific antibodies used in the present study.
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Fig. 3. Effect of the small-molecule AMPK activator 991 on activity of a panel of 139 protein kinases. A: a kinase screen was performed by the International
Centre for Kinase Profiling (University of Dundee). Assays were performed in the presence of 1 M 991. Results are shown in rank order as mean percent activity
compared with controls in the absence of compound  SD. B–E: mouse embryonic fibroblasts were treated with vehicle (0.1% DMSO) or 991 (10 M) for 1
h (3 independent plates for each condition). Cell lysates were immunoblotted with the indicated antibodies (B). The indicated kinases were immunoprecipitated
from cell lysates, and in vitro kinase activity toward substrate peptide was measured (C–E) as described in MATERIALS AND METHODS. ACC, acetyl-CoA
carboxylase; RAPTOR, regulatory associated protein of mechanistic target of rapamycin; SIK3, salt-inducible kinase. Results are expressed as means  SD.
*P 	 0.05.
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Fig. 4. 991 treatment enhances AMPK activity induced by 5-aminoimidazole-4-carboxamide riboside (AICAR) or C13 in hepatocytes. Hepatocytes were isolated
from male C57BL/6NTac mice and cultured overnight as described in MATERIALS AND METHODS. Hepatocytes were untreated (control) or treated with AICAR
(0.1 mM) or C13 (10 M) for 1 h in the presence of the indicated concentrations of 991. A: IB analysis was performed with 20 g lysates using the indicated
antibodies. Representative blots are shown; n 
 3. Shorter (1 min) and longer (5 min) exposure indicate the exposure time with X-ray film. B--G: AMPK
complexes were immunoprecipitated from 50 g lysates with the indicated antibodies. AMPK activity (in duplicate) was measured in vitro as described in
MATERIALS AND METHODS. Results are expressed as means  SE; n 
 3. *Significance of AICAR or C13 versus the respective control condition (0, 0.01, or 0.1
M 991); #significance of 991 versus the respective compound (AICAR or C13) or vehicle. P 	 0.05.
E713PROMOTION OF CELLULAR AMPK ACTIVITY BY DUAL TREATMENT
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00237.2016 • www.ajpendo.org
Downloaded from www.physiology.org/journal/ajpendo by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.170) on May 24, 2018.
Copyright © 2016 American Physiological Society. All rights reserved.
higher in AMPK1-containing complexes (Fig. 4, F and G).
C13 promoted a robust increase in the activity of the
AMPK1-containing complex but not the AMPK2-contain-
ing complex. Moreover, robust increases (2- to 3-fold) in
AMPK activity of AMPK1- or AMPK2-containing com-
plexes were observed when 991 was combined in a dose-
dependent manner (Fig. 4, F and G).
We observed that 991 dose dependently (0.01 and 0.1 M)
inhibited lipogenesis (34% and 63%, respectively), which was
further reduced when it was coincubated with a low dose of
AICAR (0.03 mM) or C13 (1 M) (data not shown).
Enhanced activation of AMPK1- and AMPK3-containing
complexes by dual compound treatment in C2C12 muscle cells.
We next investigated the effects of dual compound treatment
on AMPK activity in muscle cells. We first characterized the
isoform-specific expression pattern of AMPK in C2C12 mouse
myoblasts and myotubes. We observed that in myoblasts,
expression of 1, 1, and 1 was readily detectable and their
levels did not alter when differentiated into myotubes. In
contrast, expression of 2, 2, and 3 was only detectable in
myotubes but not in myoblasts (Fig. 5A). Consistent with the
results obtained using mouse skeletal muscle tissue (Fig. 1E),
levels of AMPK2 in C2C12 myoblasts and myotubes were
undetectable (data not shown).
Incubation of C2C12 myotubes with 991 alone modestly
increased AMPK phosphorylation but only at a concentration
of 10 M (Fig. 5B). Treatment with 991 promoted dose-
dependent increases in ACC and RAPTOR phosphorylation.
Similar to the observations in hepatocytes (Fig. 4A) (18), in
muscle cells, phosphorylation of RAPTOR also appeared to
require a higher threshold of AMPK activity than ACC phos-
phorylation (Fig. 5B). Incubation with AICAR robustly pro-
moted AMPK phosphorylation, which was further increased
in a dose-dependent manner in the presence of 991. AICAR (2
mM) alone readily saturated ACC phosphorylation, whereas
RAPTOR phosphorylation was further increased in a dose-
dependent manner in the presence of 991 (Fig. 5B). We then
attempted to establish a sequential immunoprecipitation proto-
col to measure activities of AMPK1- and AMPK3-contan-
ing complexes from small volumes of muscle cell/tissue ex-
tracts. As shown in Fig. 5C and consistent with our earlier
observations (Fig. 2, A and C), incubation of lysates with
AMPK3 antibody (in complex with protein G-Sepharose)
selectively immunoprecipitated AMPK3-contaning com-
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Fig. 5. 991 treatment enhances AMPK activ-
ity induced by AICAR in C2C12 muscle cells.
A: IB analysis was performed with 20 g
lysates from C2C12 myoblasts or myotubes
with the indicated antibodies. Representative
blots are shown; n 
 2 for each condition.
Creatine kinase was used as a differentiation
marker. B: IB analysis was performed with 20
g lysates from C2C12 myotubes untreated
(control) or treated with AICAR (2 mM) in
the presence or absence of the indicated dose
of 991 for 30 min. Representative blots are
shown; n 
 3 for each condition. C: sche-
matic representation of the sequential immu-
noprecipitation protocol for the isolation of
AMPK3 and AMPK1 from tissue lysates
(top). AMPK3 and AMPK1 immune com-
plexes were sequentially immunoprecipitated
from 200 g mouse gastrocnemius muscle
lysate protein. IB analysis was then per-
formed on the input (10% 
 20 g), the SN
(10% 
 20 g), and the immunoprecipitates
(IP) from the first and second immunopre-
cipitation using the indicated antibodies (bot-
tom). D: AMPK3 and AMPK1 activity (in
duplicate) from 200 g C2C12 myotube lysate
protein were measured after sequential im-
munoprecipitations as described in MATERI-
ALS AND METHODS. Results are expressed as
means SE; n
 3. *Significance of AICAR
versus the respective control condition (0 or
10 M 991); #significance of 991 versus the
respective control (0 or 2 mM AICAR). P 	
0.05.
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plexes but not AMPK1-containing complexes. Using the
supernatant after AMPK3 immunodepletion, AMPK1-con-
taining complexes were efficiently immunoprecipitated (Fig.
5C). Activity of both AMPK1- and AMPK3-containing
complexes tended to increase after treatment with 991 alone at
a concentration of 10 M (Fig. 5, D and E), consistent with the
results of AMPK phosphorylation (Fig. 5B). In contrast, 991
treatment only further enhanced the effect of AICAR on
AMPK activity of AMPK1- and AMPK3-containing com-
plexes at a concentration of 10 M (Fig. 5, D and E).
Effect of dual compound treatment on AMPK1/3 activity
and glucose transport in mouse skeletal muscle. We tested
whether dual compound treatment further stimulated AMPK
activity and glucose transport in mouse skeletal muscle. Iso-
lated EDL muscle was incubated in the presence or absence of
991 with or without AICAR. 991 alone increased the phosphor-
ylation of AMPK and RAPTOR in a dose-dependent manner,
whereas 5 M 991 already increased phosphorylation of ACC at
maximum levels. AICAR (0.3 mM) alone robustly increased the
phosphorylation of AMPK, ACC, and RAPTOR (Fig. 6A).
Cotreatment of EDL with 991 and AICAR further promoted the
phosphorylation of AMPK and RAPTOR compared with single
treatments. Incubation of EDL with 991 (5 and 30M) caused an
almost twofold increase in 2-deoxyglucose transport, as previ-
ously described (22), although there was no dose-response
effect under the condition we tested. AICAR also tended to
increase 2-deoxyglucose transport 1.5-fold (not statistically
significant), which was further enhanced (1.5-fold) by 991 (5
and 30 M; Fig. 6B). AMPK1-containing activity was in-
creased (2.5-fold) with 30 M 991 (Fig. 6C). While AICAR
(0.3 mM) alone showed no significant increase, when coincu-
bated with a lower concentration of 991 (5 M but not 30 M),
it significantly promoted AMPK1-containing activity com-
pared with single 5 M 991 treatment (Fig. 6C). 991 (30 M)
caused a significant increase in AMPK3-containing activity.
AMPK3-containing activity was robustly increased by incu-
bation with AICAR (4-fold) and was further increased in the
presence of 991 (5 and 30 M; Fig. 6D).
Additive effects of 991 treatment and contraction on AMPK
activity and glucose transport in mouse skeletal muscle. We
next examined if the effect of 991 on AMPK activity and
glucose transport could be further stimulated when combined
with contraction in mouse skeletal muscle ex vivo. We have
previously observed that intense tetanic contraction [100 Hz,
which causes a robust (4-fold) increase in muscle glucose
uptake] failed to elicit an additive effect when combined with
various doses of 991 (22). It might be the case that under such
a high-intensity contraction protocol, glucose transport through
GLUT4 translocation got saturated and thus there was no room
for further increase when 991 was added. Therefore, we used
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Fig. 6. Dual compound treatment further increases AMPK activity and glucose transport in mouse skeletal muscle compared with single compound treatment.
EDL muscles from C57BL/6 mice were isolated and incubated in the presence or absence of the indicated compounds (and concentrations) for 1 h followed by
the 2-deoxyglucose (2-DG) transport assay as described in MATERIALS AND METHODS. A: IB analysis was performed with 20 g muscle lysate protein with the
indicated antibodies. Representative blots are shown; n 
 4. B: 2-DG transport (n 
 4). C and D: AMPK complexes were immunoprecipitated from 200 g
muscle lysate protein using either AMPK1 (C) or AMPK3 (D) antibody. AMPK activity was measured as described in MATERIALS AND METHODS. Results are
expressed as means  SE; n 
 4. *Significance of AICAR versus the respective control condition (0, 5, or 30 M 991); #significance between 991 and the
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a low/moderate-intensity twitch (1 Hz) contraction protocol,
which causes submaximal glucose transport (42). Isolated
mouse EDL muscle was incubated with 991 (5 M) for 45
min, and the muscle was then either electrically stimulated
(contraction) or further incubated (control) with or without 991
for 15 min. As shown in Fig. 7A, 991 treatment alone modestly
increased AMPK phosphorylation (longer exposure), which
was associated with increases in the phosphorylation of ACC
and RAPTOR. Contraction increased AMPK phosphorylation
much more robustly compared with 991, whereas the increases
in phosphorylation of ACC and RAPTOR were similar to those
induced by 991. Treatment with 991 and electrical stimulation
in combination resulted in modest additional increases in the
phosphorylation of AMPK and RAPTOR (Fig. 7A). Treat-
ment with 991 or contraction alone significantly increased
2-deoxyglucose transport to the same extent (2-fold; Fig.
7B). When 991 treatment and contraction were combined, an
additive increase in 2-deoxyglucose transport was observed.
We next assessed if the activities of AMPK1- and
AMPK3-contaning complexes were increased in response to
contraction and whether the increase was enhanced when
combined with 991 treatment. 991 treatment resulted in a
modest but nonsignificant increase in AMPK activity of
AMPK1- and AMPK3-containing complexes (Fig. 7, C and
D). Contraction robustly increased activities of both AMPK1-
and AMPK3-containing complexes, which were further in-
creased when 991 treatment and contraction were combined
(Fig. 7, C and D).
DISCUSSION
There has been keen interest in developing AMPK-activat-
ing drugs for therapeutic use in treating metabolic diseases
such as type 2 diabetes. AMPK is involved in a plethora of
biological/physiological events, which could partly be ex-
plained by the fact that AMPK exists theoretically as 12
distinct trimeric complexes (excluding splice variants) that are
uniquely distributed across different cell types/tissues. There-
fore, activators that specifically target different isoforms/com-
plexes of AMPK hold promise in drug development for the
treatment of specific symptoms/disorders, possibly with fewer
off-target effects. Isoform-specific activators also represent
valuable research tools to study AMPK functions in intact
cells/tissues. Although several studies have reported expres-
sion profiles of AMPK isoforms/complexes in mouse skeletal
muscles (43), the specificity of the antibodies used was not
perfectly documented and validated. In the present study, we
first carried out a comprehensive characterization/validation of
AMPK isoform-specific antibodies for immunoblot analysis
and immunoprecipitation using tissue extracts from AMPK
isoform-specific KO mouse models as negative controls. Tak-
ing advantage of the validated antibodies, we also assessed the
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Fig. 7. 991 and contraction additively increase AMPK activity and glucose transport in mouse skeletal muscle. EDL muscles from C57BL/6 mice were isolated
and incubated in the presence or absence of 991 (5 M) for 45 min. Muscles were then either electrically stimulated to induce contraction or further incubated
(no electrical stimulation) for 15 min. 2-DG transport was measured during the last 10 min of contraction or incubation as described in MATERIALS AND METHODS.
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expression of AMPK isoforms in different mouse skeletal
muscles and other tissues. It has been controversial whether the
AMPK 2-isoform is expressed in muscle. One study showed
the presence/detection of AMPK2 in mouse skeletal muscle
tissues assessed by immunoblot analysis but failed to detect it
in AMPK complexes associated with 1/2 or 1/2 (43).
Using a newly generated AMPK2-deficient mouse model, we
showed that the full-length AMPK2 variant is not expressed
at detectable levels in mouse hindlimb skeletal muscles. We
speculate that the previously detected immunoreactivity was
nonspecific. Using AMPK3 KO muscle lysates, we also
confirmed that AMPK3 is only detectable in skeletal muscle
and is expressed in glycolytic (e.g., EDL) and glycolytic-
oxidative mixed (e.g., gastrocnemius) but not oxidative (e.g.,
soleus) mouse muscles, as previously described (2, 49). More-
over, we observed that AMPK3 (as well as AMPK2 and
AMPK2) is not detectable in C2C12 myoblasts but is induced
upon differentiation into myotubes. Although the molecular
mechanism by which AMPK3 expression is controlled re-
mains unknown, the involvement of coactivator-associated
arginine methyltransferase 1/protein arginine methyltrans-
ferase 4 has been shown in the regulation of AMPK3 expres-
sion and that of other genes involved in glycogen metabolism
in C2C12 muscle cells (44).
We (8, 11, 41) and others (35) have recently shown that dual
AMPK-activating compound treatment (A769662 and
AICAR) resulted in additive/synergistic increases in cellular
AMPK activity and downstream physiological effects such as
the inhibition of lipogenesis in hepatocytes (8) and glucose
transport in cardiomyocytes (41). One limitation of using
A769662 in dual treatment is that it is only effective in cells
where 1 is predominantly expressed. Although both A769662
and 991 bind to the ADaM site (4, 23, 46), 991 is much more
potent than A769662 (in assays monitoring allosteric activation
and protection against dephosphorylation using recombinant
211 complexes) (46). However, it should be noted that
even though 991 increases AMPK activity of both 1- and
2-containing complexes, it binds to 1-containing complexes
10 times stronger than to 2-containing complexes in cell-
free assays (46) (which possibly explains its weaker activation
of 2-complexes versus 1-complexes in vitro and also in
intact cells; Fig. 4E). Nonetheless, we demonstrated that 991
increases AMPK activity of both 1- and 2-containing com-
plexes and thus, as anticipated, it also activates AMPK1-/2-
and AMPK1-/2-containing complexes in hepatocytes. We
also showed that the effects of 991 on cellular AMPK activity
in hepatocytes can be further enhanced (as judged by a dose-
dependent increase in RAPTOR phosphorylation) in the pres-
ence of AICAR or C13. Moreover, we showed here that 1-
and 3-complex activity as well as glucose transport were
additively/synergistically enhanced when 991 and AICAR
were combined, indicating that the dual treatment approach can
work in various different cell systems irrespective of the
composition of the -subunit.
Recently, the effect of another small-molecule AMPK acti-
vator, PT-1, on AMPK activity and glucose uptake in mouse
skeletal muscle was investigated (20). An unexpected obser-
vation reported in that study (20) was that although PT-1 was
initially thought to activate AMPK by direct binding between
the kinase and auto-inhibitory domains of the -subunit (28),
Jensen et al. showed that PT-1 failed to activate AMPK
directly but rather indirectly activated it by inhibiting the
respiratory chain and increasing cellular AMP-to-ATP and/or
ADP-to-ATP ratios (20). Nevertheless, they showed that PT-
1-activated AMPK associated only with AMPK1- and not
AMPK3-containing complexes, which resulted in no signifi-
cant increase in ACC2 and TBC1 domain family member 1
phosphorylation and no increase in glucose transport in mouse
skeletal muscle. Although the mechanism by which PT-1
preferentially activates AMPK1-containing complexes (par-
ticularly in mouse skeletal muscle) is unknown, the study by
Jensen et al. (20) indicated that activation of AMPK3-con-
taining complexes is required to increase glucose transport in
intact mouse skeletal muscle. It has been well documented that
AICAR stimulates glucose transport in mouse skeletal muscle
in an AMPK-dependent mechanism based on a study using
AMPK-deficient genetic mouse models (30). It has recently
been shown that 991 treatment stimulates glucose transport in
mouse skeletal muscle and that the 991-mediated increase in
glucose transport was absent in AMPK1/2 KO cultured
myotubes (22). We showed in mouse EDL muscle that both 5
M 991 and contraction significantly increased glucose trans-
port to a similar extent (2-fold), although AMPK activity of
1-and 3-containing complexes was much greater in con-
tracted muscles. However, it should be noted that 991 increases
AMPK activity not only through protection against dephos-
phorylation leading to AMPK T172 phosphorylation-depen-
dent activation but also via potent allosteric stimulation
through the ADaM site (46). Given that measurement of
AMPK activity in vitro only assesses phosphorylation (T172)-
dependent activation, it is possible that 221/223 com-
plexes are allosterically activated in intact muscle by 991. This
may at least partly explain why phosphorylation of bona fide
AMPK substrates (ACC and RAPTOR) and the extent of
glucose transport were comparable between 991- and contrac-
tion-stimulated muscles. It would be of interest to identify
1-and 3-complex-specific substrate(s) (if any) and monitor
their cellular activity upon 991 treatment through its/their
phosphorylation by immunoblot analysis. In addition, whether
AMPK3 is necessary for 991-stimulated glucose uptake, like
AICAR, would be interesting to test using an AMPK3 KO
mouse model.
In summary, we demonstrated that 991 treatment increases
AMPK activity of both AMPK1- and AMPK3-containing
complexes in mouse skeletal muscle. We also showed that dual
treatment with 991 and AICAR or 991 and contraction aug-
ments AMPK activation and glucose transport compared with
single treatment. The dual treatment approach has proven to be
useful to robustly activate cellular AMPK, thereby facilitating
the identification of new AMPK substrates in different cell
types (7, 17). Next, it would be of interest to test if dual
treatment (combinations of various compounds or compound
plus exercise/contraction) also promotes AMPK activity and
glucose transport in vivo.
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